Business Description
Oncotelic Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US57667K1097
Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.01 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 1.46 | |||||
| Debt-to-EBITDA | -3.19 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 40.6 | |||||
| 3-Year EPS without NRI Growth Rate | 69.5 | |||||
| 3-Year FCF Growth Rate | 54.6 | |||||
| 3-Year Book Growth Rate | -38.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.5 | |||||
| 9-Day RSI | 51.36 | |||||
| 14-Day RSI | 51.11 | |||||
| 6-1 Month Momentum % | -5.41 | |||||
| 12-1 Month Momentum % | -12.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.01 | |||||
| Quick Ratio | 0.01 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -63.9 | |||||
| Shareholder Yield % | -6.35 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -1441.43 | |||||
| ROE % | -40.5 | |||||
| ROA % | -15.87 | |||||
| ROIC % | -1.07 | |||||
| ROCE % | -31.6 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.51 | |||||
| Price-to-Tangible-Book | 3.01 | |||||
| EV-to-EBIT | -6.34 | |||||
| EV-to-EBITDA | -6.34 | |||||
| EV-to-Revenue | 366.76 | |||||
| EV-to-Forward-Revenue | 34.57 | |||||
| EV-to-FCF | -25.44 | |||||
| Earnings Yield (Greenblatt) % | -15.77 | |||||
| FCF Yield % | -8.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:OTLC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncotelic Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.07 | ||
| EPS (TTM) ($) | -0.012 | ||
| Beta | -0.08 | ||
| Volatility % | 69.92 | ||
| 14-Day RSI | 51.11 | ||
| 14-Day ATR ($) | 0.004765 | ||
| 20-Day SMA ($) | 0.029492 | ||
| 12-1 Month Momentum % | -12.5 | ||
| 52-Week Range ($) | 0.017 - 0.045 | ||
| Shares Outstanding (Mil) | 407.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncotelic Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncotelic Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oncotelic Therapeutics Inc Frequently Asked Questions
What is Oncotelic Therapeutics Inc(OTLC)'s stock price today?
The current price of OTLC is $0.03. The 52 week high of OTLC is $0.05 and 52 week low is $0.02.
When is next earnings date of Oncotelic Therapeutics Inc(OTLC)?
The next earnings date of Oncotelic Therapeutics Inc(OTLC) is 2025-02-19 Est..
Does Oncotelic Therapeutics Inc(OTLC) pay dividends? If so, how much?
Oncotelic Therapeutics Inc(OTLC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers